Arcutis Biotherapeutics (ARQT) Other Non-Current Assets (2019 - 2026)

Arcutis Biotherapeutics (ARQT) posted quarterly Other Non-Current Assets of $2.3 million for Q1 2026, up 285.23% year-over-year from $596000.0 in Q1 2025, and up 61.8% quarter-over-quarter from $1.4 million in Q4 2025.

Arcutis Biotherapeutics (ARQT) Other Non-Current Assets (2019 - 2026) Analysis & Trends

Arcutis Biotherapeutics' Other Non-Current Assets history runs 8 years deep, the most recent figure standing at $2.3 million for Q1 2026.

  • In Q1 2026, Other Non-Current Assets rose 285.23% year-over-year to $2.3 million; the TTM figure through Mar 2026 stood at $2.3 million (up 285.23% YoY), while the FY2025 annual figure was $1.4 million, up 138.09% from the prior year.
  • Other Non-Current Assets for Q1 2026 stood at $2.3 million, up from $1.4 million in the prior quarter.
  • The five-year high for Other Non-Current Assets was $2.3 million in Q1 2026, with the low at $78000.0 in Q1 2022.
  • The 5-year median for Other Non-Current Assets is $596000.0 (2023), against an average of $592000.0.
  • The sharpest annual moves came in 2023 and 2024: Other Non-Current Assets soared 664.1% in 2023, then dropped 0.17% in 2024.
  • Arcutis Biotherapeutics' Other Non-Current Assets stood at $78000.0 in 2022, then jumped by 664.1% to $596000.0 in 2023, then changed by 0.0% to $596000.0 in 2024, then jumped by 138.09% to $1.4 million in 2025, then jumped by 61.8% to $2.3 million in 2026.
  • Business Quant data shows ARQT's Other Non-Current Assets at $2.3 million in Q1 2026, $1.4 million in Q4 2025, and $596000.0 in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Other Non-Current Assets (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn 1.25 Bn
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 2.31 Bn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn 124.00 Mn
4 Revolution Medicines 43.64 Bn 43.64 Bn - 42.45 Mn
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 109.58 Mn
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn 18,237.65
7 Royalty Pharma 33.72 Bn 35.84 Bn - 62.96 Mn
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn 65.13 Mn
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn 104.44 Mn
10 Arcutis Biotherapeutics 3.29 Bn 3.05 Bn 118.92 Mn 2.05 Mn

Historic Data

Download Data
DateValue
Jun 30, 2026 2.05 Mn
Mar 31, 2026 2.30 Mn
Dec 31, 2025 1.42 Mn
Sep 30, 2025 596,000.00
Jun 30, 2025 596,000.00
Mar 31, 2025 596,000.00
Dec 31, 2024 596,000.00
Sep 30, 2024 596,000.00
Jun 30, 2024 595,000.00
Mar 31, 2024 596,000.00
Dec 31, 2023 596,000.00
Sep 30, 2023 596,000.00
Jun 30, 2023 596,000.00
Mar 31, 2023 78,000.00
Dec 31, 2022 78,000.00
Sep 30, 2022 78,000.00
Jun 30, 2022 78,000.00
Mar 31, 2022 78,000.00
Dec 31, 2021 78,000.00
Sep 30, 2021 78,000.00